XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 33.34

-2.1%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: bob zagorin who wrote (17244)	10/11/2006 10:52:12 AM
From: bob zagorin	of 17367

from yahoo...can't vouch for accuracy ".... LUCENTIS -$153M, RAPTIVA-$23M (Not rated) 10-Oct-06 04:54 pm XOMA will receive royalities ~$1.2M (0.75%) from LUCENTIS sale and ~$2.3 from RAPTIVA (DNA $23M + SRA $17M). -- U.S. sales of LUCENTIS(TM) (ranibizumab injection) were $153 million. Approved and launched on June 30, 2006, sales in the second quarter of 2006 were $10 million. -- U.S. sales of RAPTIVA® (efalizumab) increased 10 percent to $23 million, from $21 million in the third quarter of 2005..."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next